FDA Adverse Event Injury Summary report: N

EVOLUT FX DCS

MDR report key: 23512677 · Received November 10, 2025

Report

Report Number
9612164-2025-05530
Event Type
Injury
Date Received
November 10, 2025
Date of Event
October 16, 2025
Report Date
December 8, 2025
Manufacturer
MEDTRONIC IRELAND
Product Code
NPT
UDI-DI
00763000365684
PMA / PMN Number
P130021
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

CONTINUATION OF D10:  PRODUCT ID EVFXPLUS-34 (K943659); PRODUCT TYPE: 0195-HEART VALVES; IMPLANT DATE N/A; EXPLANT DATE N/A MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Additional Manufacturer Narrative · 0

UPDATED DATA: B5. A SECOND PARAGRAPH WAS ADDED. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Description of Event or Problem · 0

IT WAS REPORTED THAT DURING THE ATTEMPTED IMPLANT OF A TRANSCATHETER VALVE, UPON THE FIRST DEPLOYMENT ATTEMPT, THE VALVE WAS RECAPTURED DUE TO THE IMPLANT DEPTH BEING TOO HIGH. UPON RECAPTURE, AN INFOLD WAS OBSERVED. A SECOND DEPLOYMENT ATTEMPT WAS PERFORMED, AND THE INFOLD WAS STILL PRESENT. IT WAS NOTED THAT THE TARGET IMPLANT DEPTH WHEN THE INFOLD OCCURRED WAS 2 MILLIMETERS (MM). SUBSEQUENTLY, THE VALVE WAS RECAPTURED AND WITHDRAWN FROM THE PATIENT, AND A NEW TRANSCATHETER VALVE AND NEW DELIVERY CATHETER SYSTEM (DCS) WERE USED. UPON DEPLOYMENT OF THE NEW VALVE, THE IMPLANT DEPTH WAS 3 MM ON THE NON-CORONARY CUSP (NCC) AND 3 MM ON THE LEFT CORONARY CUSP (LCC). SUBSEQUENTLY, THE VALVE WAS FULLY DEPLOYED; HOWEVER, "SOME" PARAVALVULAR LEAK (PVL) WAS NOTED. A POST-IMPLANT BALLOON AORTIC VALVULOPLASTY (BAV) WAS PERFORMED USING A 26 MM NON-MEDTRONIC BALLOON WHILE THE PATIENT WAS RAPIDLY PACED OFF THE MEDTRONIC GUIDEWIRE AS VENOUS ACCESS WAS UNABLE TO BE OBTAINED. DURING THE POST-IMPLANT BAV, PREMATURE VENTRICULAR CONTRACTION (PVC) WAS OBSERVED, AND THE VALVE DISLODGED AORTIC BEFORE THE BALLOON WAS DOWN. SUBSEQUENTLY, THE VALVE WAS SNARED IN PLACE ABOVE THE SINOTUBULAR JUN CTION (STJ) WHILE A SECOND TRANSCATHETER VALVE WAS LOADED AND IMPLANTED. FOLLOWING THE IMPLANT OF THE SECOND VALVE, MILD TO MODERATE PVL WAS NOTED; HOWEVER, NO FURTHER INTERVENTION WAS PERFORMED. IT WAS ALSO REPORTED THAT THE PATIENT HAD A PERIPHERAL ILIAC ARTERY COMPLICATION THAT WAS MANAGED WITH ILIAC STENTS. IT WAS NOTED THAT A 1 HOUR PROCEDURAL DELAY OCCURRED. PER THE PHYSICIAN, THE LOSS OF PACING CONTRIBUTED TO THE EVENT.

Description of Event or Problem · 0

IT WAS REPORTED THAT DURING THE ATTEMPTED IMPLANT OF A TRANSCATHETER VALVE, UPON THE FIRST DEPLOYMENT ATTEMPT, THE VALVE WAS RECAPTURED DUE TO THE IMPLANT DEPTH BEING TOO HIGH. UPON RECAPTURE, AN INFOLD WAS OBSERVED. A SECOND DEPLOYMENT ATTEMPT WAS PERFORMED, AND THE INFOLD WAS STILL PRESENT. IT WAS NOTED THAT THE TARGET IMPLANT DEPTH WHEN THE INFOLD OCCURRED WAS 2 MILLIMETERS (MM). SUBSEQUENTLY, THE VALVE WAS RECAPTURED AND WITHDRAWN FROM THE PATIENT, AND A NEW TRANSCATHETER VALVE AND NEW DELIVERY CATHETER SYSTEM (DCS) WERE USED. UPON DEPLOYMENT OF THE NEW VALVE, THE IMPLANT DEPTH WAS 3 MM ON THE NON-CORONARY CUSP (NCC) AND 3 MM ON THE LEFT CORONARY CUSP (LCC). SUBSEQUENTLY, THE VALVE WAS FULLY DEPLOYED; HOWEVER, "SOME" PARAVALVULAR LEAK (PVL) WAS NOTED. A POST-IMPLANT BALLOON AORTIC VALVULOPLASTY (BAV) WAS PERFORMED USING A 26 MM NON-MEDTRONIC (Z MED) BALLOON WHILE THE PATIENT WAS RAPIDLY PACED OFF THE MEDTRONIC (CONFIDA) GUIDEWIRE AS VENOUS ACCESS WAS UNABLE TO BE OBTAINED. DURING THE POST-IMPLANT BAV, PREMATURE VENTRICULAR CONTRACTION (PVC) WAS OBSERVED, AND THE VALVE DISLODGED AORTIC BEFORE THE BALLOON WAS DOWN. SUBSEQUENTLY, THE VALVE WAS SNARED IN PLACE ABOVE THE SINOTUBULAR JUNCTION (STJ) WHILE A SECOND TRANSCATHETER VALVE WAS LOADED AND IMPLANTED. FOLLOWING THE IMPLANT OF THE SECOND VALVE, MILD-MODERATE PVL WAS NOTED; HOWEVER, NO FURTHER INTERVENTION WAS PERFORMED. IT WAS ALSO REPORTED THAT THE PATIENT HAD A PERIPHERALILIAC ARTERY COMPLICATION THAT WAS MANAGED WITH ILIAC STENTS. IT WAS NOTED THAT A 1 HOUR PROCEDURAL DELAY OCCURRED. PER THE PHYSICIAN, THE LOSS OF PACING CONTRIBUTED TO THE EVENT. ADDITIONAL INFORMATION WAS RECEIVED TO REPORT THE RIGHT FEMORAL ARTERY WAS USED FOR THE DCS VASCULAR ACCESS WHICH HAD A MINIMUM DIAMETER OF 7MM. THE SEVERITY OF PVL NOTED WITH THE FIRST VALVE WAS MILD-MODERATE. IT WAS NOTED THE STARTING POINT OF DEPLOYMENT WAS AT THE MIDDLE OF THE PIGTAIL. IT WAS ALSO NOTED IN TERMS OF PATIENT ANATOMY, "NO LOSS OF CAPTURE" CONTRIBUTED TO THE DISLODGEMENT. A SECOND DCS WAS USED TO IMPLANT THE SECOND VALVE. THE PERIPHERAL ILIAC ARTERY COMPLICATION WAS SPECIFIED AS A BLEED AT THE RIGHT ILIAC ARTERY AND OCCURRED DURING INSERTION OF AN UNSPECIFIED DEVICE; HOWEVER, THE PHYSICIAN INDICATED THE DCS AND CONFIDA GUIDEWIRE DID NOT CAUSE THE INJURY. CONFLICTING INFORMATION WAS RECEIVED WHETHER THE INJURY WAS DUE TO ANATOMICAL COMPLICATIONS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1962643 EVOLUT FX DCS AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV NPT MEDTRONIC IRELAND D-EVOLUTFX-34 0012101422 00763000365684

Patients

Seq Age Sex Outcome Treatment
1 89 YR Male Required Intervention SEE H11...